导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.33% | 3536/4763 |
| 近一周 | -1.11% | 1689/5452 |
| 近一月 | -8.17% | 4790/5409 |
| 近一季 | -4.42% | 1810/5219 |
| 近半年 | -10.53% | 3693/4908 |
| 近一年 | -12.84% | 3574/4388 |
| 近两年 | 60.65% | 1217/2951 |
| 近三年 | 11.15% | 1723/2250 |
| 成立以来 | -13.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.54% 3644/4961 |
11.07% 2371/5312 |
- - |
- - |
| 2025 | 13.32% 2649/4813 |
4.99% 849/3635 |
-2.01% 3294/4076 |
22.51% 1643/4524 |
-10.10% 4132/4813 |
| 2024 | 9.80% 1447/3463 |
-5.93% 1979/2808 |
-11.60% 2553/3014 |
18.61% 977/3129 |
11.32% 223/3463 |
| 2023 | -1.52% 519/2656 |
34.53% 56/2280 |
-8.93% 2022/2385 |
-14.93% 2202/2515 |
-5.52% 1380/2655 |
| 2022 | -25.66% 1338/2207 |
-21.19% 1606/1919 |
-2.61% 1782/2016 |
-14.17% 1041/2113 |
12.84% 120/2208 |
| 2021 | -0.96% 772/1822 |
-6.47% 1005/1255 |
11.50% 371/1330 |
-8.55% 1138/1466 |
3.85% 385/1822 |
| 2020 | 20.72% 707/1250 |
4.40% 73/1028 |
16.42% 440/1067 |
-0.34% 1053/1164 |
-0.35% 1072/1184 |
| 2019 | 48.65% 112/1092 |
47.07% 13/754 |
-9.15% 634/804 |
6.59% 119/850 |
4.37% 805/918 |
| 2018 | -25.07% 339/834 |
- - |
- - |
- - |
-13.38% 531/691 |
| 2017 | -1.94% 497/714 |
- - |
- - |
- - |
- - |
| 2016 | -32.36% 510/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证计算机ETF联接A VS. 长安沪深300非周期A(740101) |